- Centers & Specialties
- Clinical Interests
- Cancer prevention
- Colon and rectal cancer
- Hereditary colorectal cancer
- Gastrointestinal cancer
- Medical Education
- MD, Harvard Medical School
- MPH, Harvard School of Public Health
- Residency, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital
- Board Certifications
- Boston: Massachusetts General Hospital
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- Cigna (PAL #'s)
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - other
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
- Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, Inamura K, Kim SA, Kuchiba A, Yamauchi M, Imamura Y, Willett WC, Rosner BR, Fuchs CS, Giovannucci E, Ogino S , Chan AT (co-senior authors). Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013. 369(12):1095-105.
- Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, Liao X, Imamura Y, Qian ZR, Morikawa T, Wang M, Spiegelman D, Cho E, Giovannucci E, Fuchs CS, Chan AT , Ogino S (co-senior authors). Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA. 2013. 309: 2563-71. PMCID: PMC3743040
- Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian Z, Baba Y, Shima K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT , Ogino S (co-senior authors). Aspirin use, PIK3CA mutation, and colorectal cancer survival. N Engl J Med. 2012; 367: 1596-606. PMCID: PMC3532946
- Chan AT, Ogino S, Giovannucci EL, Fuchs CS. Inflammatory markers are associated with risk of colorectal cancer and chemopreventative response to anti-inflammatory drugs. Gastroenterology. 2011. 140(3): 799-808. PMCID: PMC3049858
- Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302(6):649-58. PMCID: PMC2848289. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356(21):2131-42.
The 69th meeting of the MGH Scientific Advisory Committee (SAC), on April 6 and 7, focused on the hospital’s five thematic research centers.
An analysis of data from two major, long-term epidemiologic studies finds that the regular use of aspirin significantly reduces the overall risk of cancer, a reduction that primarily reflects a lower risk of colorectal cancer and other tumors of the gastrointestinal tract.
Researchers from MGH, Dana-Farber Cancer Institute and Case Western Reserve School of Medicine have shown that aspirin’s previous reported ability to reduce the risk of colorectal cancer applies only to individuals with high levels of a specific gene product in their colons.
A new study finds that colonoscopy appears to reduce the risk of developing or dying from colorectal cancer more powerfully than does sigmoidoscopy, a similar procedure that examines only a portion of the colon. The investigation also identifies molecular features that may help explain tumors that are diagnosed despite an individual's having recently undergone colonoscopy.
Aspirin's ability to protect against colorectal cancer may depend on risk-associated inflammatory pathways
The reduced risk of colorectal cancer associated with taking aspirin or other nonsteroidal anti-inflammatory drugs may be limited to individuals already at risk because of elevations in a specific inflammatory factor in the blood.
Regular use of aspirin after colorectal cancer diagnosis may reduce the risk of cancer death, report investigators from Massachusetts General Hospital, Dana-Farber Cancer Institute and Brigham and Women’s Hospital.
Aspirin therapy's ability to reduce the risk of colorectal cancer, an association seen in a large number of studies, appears to depend on the drug's inhibition of the COX-2 enzyme, the action that also underlies aspirin's usefulness for treating pain and inflammation.
quotes MGH investigator Andrew Chan
quotes MGH physician Andrew Chan
55 Fruit Street
Boston, MA 02114-2696